Effects of spore-forming probiotic Bacillus subtilis HU58™ in children with antibiotic-associated diarrhoea: a randomised, double-blind, placebo-controlled trial
Beneficial Microbes · 2025
DOI: 10.1163/18762891-bja00086 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Beneficial Microbes, 2025. Verfasst von K Sorensen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, 1451Novozymes A/S, Krogshøjvej 36, 2880 Bagsvaerd, Denmark. Hauptthemen laut MEDLINE: Probiotics, Diarrhea, Bacillus subtilis, Anti-Bacterial Agents. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Antibiotics are among the most prescribed medicines in children globally. Antibiotic-associated diarrhoea (AAD) and associated abdominal pain are common side effects, caused by alterations to the intestinal microbiota composition. Most research on probiotic interventions involves prophylactic use of Saccharomyces , lactobacilli or bifidobacteria. Less is known about spore-forming strains administered after AAD onset. Bacillus subtilis HU58™ was found to improve AAD symptoms in adults. This randomised, double-blind, placebo-controlled trial in India investigated the effects of a dietary supplement containing B. subtilis HU58 (2 × 10 9 cfu/day) versus placebo for seven days on diarrhoea duration (Bristol Stool Scale, BSS), abdominal pain intensity (Visual Analogue Scale, VAS), and overall gastrointestinal wellbeing (adapted Gastrointestinal Restoration Questionnaire, GIRQ; Physician Global Assessment, PGA) in 68 children (1-12 years) with AAD. Between-group comparison of data from each timepoint was conducted for the intention to treat population (Chi-squared test of independence for distribution of BSS types, Wilcoxon rank sum test for mean BSS types, mixed model for repeated measures for VAS, GIRQ and PGA scores). By day 3, 93.5% of the probiotic group had normal BSS types, versus 22.6% in the placebo group ( ). Almost all subjects in both groups had normal stool types by day 7. Significantly greater decreases in abdominal pain VAS scores were observed among those receiving the probiotic versus placebo at day 3 (−7.4 [SE 0.5] versus −1.9 [SE 0.3], ) and day 7 (−9.1 [SE 0.3] versus −8.5 [SE 0.2], ). Greater improvements for both adapted GIRQ and PGA scores assessing GI wellbeing were observed in the probiotic group compared to the placebo group at days 3 and 7 (all ). Spore-forming B. subtilis HU58 administered to children after onset of AAD may lead to faster resolution of diarrhoea and associated abdominal pain. Further research with daily clinical assessment and faecal microbiome analysis is warranted. The trial is registered at https://ctri.nic.in/Clinicaltrials (CTRI/2022/02/040138).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Development, 1451Novozymes A/S, Krogshøjvej 36, 2880 Bagsvaerd, Denmark.
- Paediatric Department, Dr. Pramod Jog Children's Clinic, First Floor, Sagar Apartment, Parihar Chowk, Near ITI Road, Aundh, Pune, Maharashtra 411007, India.
- Department of Family Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pimpri, Pune, Maharashtra 411018, India.
- Paediatric Department, Mankar Hospital, Plot no. 19, Narveer Tanaji Malusare Road, Anand Nagar, Pune, Maharashtra, 411051, India.
- Department of Paediatrics and Paediatric Infectious Diseases, Bharti Vidyapeeth Medical College, Pune, Maharashtra 411043, India.
- Clinical Development, Novozymes Berlin GmbH, Kronenstraße 63, 10117 Berlin, Germany.
ORCID-Profile: K Sorensen, P Jog, C Holz, S Jadhav
Zitieren
APA
Sorensen, K., Jog, P., Mankar, S., Holz, C., & Jadhav, S. (2025). Effects of spore-forming probiotic Bacillus subtilis HU58™ in children with antibiotic-associated diarrhoea: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes. https://doi.org/10.1163/18762891-bja00086
Vancouver
Sorensen K, Jog P, Mankar S, Holz C, Jadhav S. Effects of spore-forming probiotic Bacillus subtilis HU58™ in children with antibiotic-associated diarrhoea: a randomised, double-blind, placebo-controlled trial. Beneficial Microbes. 2025. doi:10.1163/18762891-bja00086
BibTeX
@article{Sorensen2025,
author = {Sorensen, K and Jog, P and Mankar, S and Holz, C and Jadhav, S},
title = {Effects of spore-forming probiotic Bacillus subtilis HU58™ in children with antibiotic-associated diarrhoea: a randomised, double-blind, placebo-controlled trial},
journal = {Beneficial Microbes},
year = {2025},
doi = {10.1163/18762891-bja00086}
}
EUVIMED